HRP20231405T1 - Liječenje upale pluća - Google Patents
Liječenje upale pluća Download PDFInfo
- Publication number
- HRP20231405T1 HRP20231405T1 HRP20231405TT HRP20231405T HRP20231405T1 HR P20231405 T1 HRP20231405 T1 HR P20231405T1 HR P20231405T T HRP20231405T T HR P20231405TT HR P20231405 T HRP20231405 T HR P20231405T HR P20231405 T1 HRP20231405 T1 HR P20231405T1
- Authority
- HR
- Croatia
- Prior art keywords
- substance
- pneumonia
- use according
- empty liposome
- empty
- Prior art date
Links
- 206010035664 Pneumonia Diseases 0.000 title claims 20
- 239000002502 liposome Substances 0.000 claims 18
- 239000000126 substance Substances 0.000 claims 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 14
- 235000012000 cholesterol Nutrition 0.000 claims 7
- 238000002560 therapeutic procedure Methods 0.000 claims 6
- 230000003115 biocidal effect Effects 0.000 claims 5
- 238000001990 intravenous administration Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 150000002632 lipids Chemical class 0.000 claims 3
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 claims 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 2
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 claims 2
- 208000022218 streptococcal pneumonia Diseases 0.000 claims 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 2
- 241000588626 Acinetobacter baumannii Species 0.000 claims 1
- 241000588832 Bordetella pertussis Species 0.000 claims 1
- 241000194031 Enterococcus faecium Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000606768 Haemophilus influenzae Species 0.000 claims 1
- 241000588747 Klebsiella pneumoniae Species 0.000 claims 1
- 241000589248 Legionella Species 0.000 claims 1
- 208000007764 Legionnaires' Disease Diseases 0.000 claims 1
- 241000588655 Moraxella catarrhalis Species 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 1
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 claims 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 claims 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 241000607715 Serratia marcescens Species 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 241000122973 Stenotrophomonas maltophilia Species 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229940047650 haemophilus influenzae Drugs 0.000 claims 1
- 229940127249 oral antibiotic Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. Tvar koja sadrži, poželjno se sastoji od smjese praznih liposoma, pri čemu navedena smjesa praznih liposoma sadrži, poželjno se sastoji od
(a) prvog praznog liposoma koji sadrži kolesterol, pri čemu je količina kolesterola najmanje 30% (težinski po težini); i
(b) drugog praznog liposoma koji sadrži sfingomijelin, pri čemu navedeni drugi prazni liposom (b) poželjno sadrži navedeni sfingomijelin kao jedinu lipidnu komponentu;
za upotrebu u dodatnom liječenju upale pluća kod pacijenata, pri čemu je navedena upala pluća poželjno odabrana između obične pneumonije stečene u zajednici (CAP), pneumonije stečene u bolnici (HAP) i pneumonije povezane s ventilatorom (VAP) kod pacijenata.
2. Tvar za upotrebu sukladno patentnom zahtjevu 1, naznačena time što je količina kolesterola navedenog praznog liposoma (a) 45%-55% (težinski po težini) i gdje se navedeni drugi prazni liposom (b) sastoji od sfingomijelina.
3. Tvar za upotrebu sukladno bilo kojem od patentnih zahtjeva 1 do 2, naznačena time što se navedeni prvi prazni liposom (a) sastoji od kolesterola i sfingomijelina i gdje je količina kolesterola navedenog praznog liposoma (a) oko 50% (težina sukladno težina ) i pri čemu navedena prazna smjesa liposoma sadrži najmanje 40%, poželjno najmanje 45% (težinski po težini) navedenog prvog (a) i navedenog drugog (b) praznog liposoma.
4. Tvar za upotrebu sukladno bilo kojem od patentnih zahtjeva 1 do 3, naznačena time što se spomenuta smjesa praznih liposoma sastoji od omjera smjese 1:1 (težinski sukladno težini - wt/wt) navedenih prvih praznih liposoma i navedenih drugih liposoma, pri čemu se navedeni prvi prazni liposom sastoji od težinskog omjera 1:1 (1:1 w/w; 35:65 molarni omjer) kolesterola i sfingomijelina i pri čemu je navedeni drugi prazni liposom sastavljen isključivo od sfingomijelina i pri čemu navedeni prvi prazni liposom (a) sadrži navedeni prvi kolesterol i navedeni sfingomijelin kao jedine lipidne komponente, a navedeni drugi prazni liposom (b) sadrži navedeni sfingomijelin kao jedinu lipidnu komponentu.
5. Tvar za upotrebu sukladno bilo kojem od patentnih zahtjeva 1 do 4, naznačena time što je navedena uobičajena upala pluća stečena u zajednici (CAP).
6. Tvar za upotrebu sukladno bilo kojem od patentnih zahtjeva 1 do 5, naznačena time što je navedena upala pluća teški oblik upale pluća, pri čemu je navedeni teški oblik upale pluća poželjno odabran između teškog oblika vanbolničke pneumonije (sCAP) i teškog oblika zajednice - stečena pneumokokna pneumonija (sCAPP).
7. Tvar za upotrebu sukladno bilo kojem od patentnih zahtjeva 1 do 6, pri čemu je navedena upala pluća poželjno teški oblik upale pluća, pri čemu je navedena upala pluća uzrokovana Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, Enterococcus faecium, Legionella pneumophilia, Haemophilus influenzae, Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumanii, Bordetella pertussis, Serratia marcescens, Stenotrophomonas maltophilia, Moraxella catarrhalis ili Mycobacterium tuberculosis.
8. Tvar za upotrebu sukladno bilo kojem od patentnih zahtjeva 1 do 7, naznačena time što je navedena streptokokna pneumonija uzrokovana Streptococcus pneumoniae.
9. Tvar za upotrebu sukladno bilo kojem od patentnih zahtjeva 1 do 8, naznačena time što je navedeni tretman komplementaran antibiotskoj terapiji.
10. Tvar za upotrebu sukladno patentnom zahtjevu 9, naznačena time što je navedena antibiotska terapija intravenozna (IV) ili oralna antibiotska terapija.
11. Tvar za upotrebu sukladno bilo kojem od patentnih zahtjeva 1 do 10, pri čemu se navedena tvar isporučuje u najmanje 2 doze, prvoj dozi i drugoj dozi, i pri čemu je interval između navedene prve doze i navedene druge doze 6 do 96 sati, poželjno 12 do 72 sata, poželjnije 24 do 48 sati i opet poželjnije 24 ili 48 sati.
12. Tvar za upotrebu sukladno bilo kojem od patentnih zahtjeva 1 do 11, naznačena time što se navedena tvar isporučuje u obliku otopine za intravenozno davanje.
13. Tvar za upotrebu sukladno bilo kojem od patentnih zahtjeva 1 do 12, naznačena time što se navedena tvar isporučuje u najmanje 2 doze, pri čemu se prva doza isporučuje najviše 24 sata nakon početka navedene antibiotske terapije, poželjno intravenozno (IV) antibiotska terapija.
14. Tvar za upotrebu sukladno bilo kojem od patentnih zahtjeva 1 do 13, naznačena time što spomenuta upala pluća, poželjno navedeni teški oblik upale pluća, još poželjnije navedeni teški oblik vanbolničke pneumonije (sCAP), zahtijeva da navedeni pacijent ostane u bolnici, poželjno u jedinici intenzivne njege (ICU) i gdje je navedeni tretman dodatak antibiotskoj terapiji i gdje navedeni dodatni tretman smanjuje duljinu boravka u navedenoj bolnici u usporedbi s boravkom u bolnici bez takvog tretmana.
15. Tvar za upotrebu iz patentnog zahtjeva 14, naznačena time što je smanjenje duljine boravka u bolnici zbog navedenog dodatnog liječenja najmanje jedan dan, poželjno dva dana, poželjnije tri dana, a još poželjnije četiri dana, i još poželjnije pet dana, a još poželjnije šest dana, a još poželjnije sedam dana.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18167848 | 2018-04-17 | ||
| EP19716950.1A EP3781172B1 (en) | 2018-04-17 | 2019-04-16 | Treatment of pneumonia |
| PCT/EP2019/059826 WO2019201937A1 (en) | 2018-04-17 | 2019-04-16 | Treatment of pneumonia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231405T1 true HRP20231405T1 (hr) | 2024-03-01 |
Family
ID=62017276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231405TT HRP20231405T1 (hr) | 2018-04-17 | 2019-04-16 | Liječenje upale pluća |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US12059496B2 (hr) |
| EP (2) | EP4338743A1 (hr) |
| JP (2) | JP7411569B2 (hr) |
| KR (1) | KR20210003117A (hr) |
| CN (1) | CN112004540A (hr) |
| AU (2) | AU2019254515B9 (hr) |
| CA (1) | CA3096968A1 (hr) |
| DK (1) | DK3781172T3 (hr) |
| ES (1) | ES2959435T3 (hr) |
| FI (1) | FI3781172T3 (hr) |
| HR (1) | HRP20231405T1 (hr) |
| HU (1) | HUE064198T2 (hr) |
| LT (1) | LT3781172T (hr) |
| MX (1) | MX2020010853A (hr) |
| PL (1) | PL3781172T3 (hr) |
| PT (1) | PT3781172T (hr) |
| RS (1) | RS64891B1 (hr) |
| SI (1) | SI3781172T1 (hr) |
| SM (1) | SMT202300391T1 (hr) |
| WO (1) | WO2019201937A1 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240399118A1 (en) * | 2023-05-31 | 2024-12-05 | Isola Therapeutics, Inc. | Intraluminal local drug delivery |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013276565B2 (en) * | 2012-06-14 | 2018-12-20 | Universitaet Bern | Tailored liposomes for the treatment of bacterial infections |
-
2019
- 2019-04-16 HU HUE19716950A patent/HUE064198T2/hu unknown
- 2019-04-16 EP EP23193661.8A patent/EP4338743A1/en active Pending
- 2019-04-16 ES ES19716950T patent/ES2959435T3/es active Active
- 2019-04-16 WO PCT/EP2019/059826 patent/WO2019201937A1/en active Application Filing
- 2019-04-16 HR HRP20231405TT patent/HRP20231405T1/hr unknown
- 2019-04-16 EP EP19716950.1A patent/EP3781172B1/en active Active
- 2019-04-16 CN CN201980025863.5A patent/CN112004540A/zh active Pending
- 2019-04-16 JP JP2020555819A patent/JP7411569B2/ja active Active
- 2019-04-16 PT PT197169501T patent/PT3781172T/pt unknown
- 2019-04-16 KR KR1020207030638A patent/KR20210003117A/ko active Pending
- 2019-04-16 SM SM20230391T patent/SMT202300391T1/it unknown
- 2019-04-16 CA CA3096968A patent/CA3096968A1/en active Pending
- 2019-04-16 AU AU2019254515A patent/AU2019254515B9/en active Active
- 2019-04-16 LT LTEPPCT/EP2019/059826T patent/LT3781172T/lt unknown
- 2019-04-16 PL PL19716950.1T patent/PL3781172T3/pl unknown
- 2019-04-16 RS RS20231062A patent/RS64891B1/sr unknown
- 2019-04-16 MX MX2020010853A patent/MX2020010853A/es unknown
- 2019-04-16 FI FIEP19716950.1T patent/FI3781172T3/fi active
- 2019-04-16 DK DK19716950.1T patent/DK3781172T3/da active
- 2019-04-16 US US17/047,666 patent/US12059496B2/en active Active
- 2019-04-16 SI SI201930637T patent/SI3781172T1/sl unknown
-
2023
- 2023-10-31 JP JP2023187144A patent/JP2024023208A/ja active Pending
-
2024
- 2024-06-28 US US18/759,232 patent/US20250170061A1/en active Pending
-
2025
- 2025-02-28 AU AU2025201451A patent/AU2025201451A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019254515A1 (en) | 2020-11-05 |
| WO2019201937A1 (en) | 2019-10-24 |
| AU2019254515B2 (en) | 2024-12-12 |
| JP7411569B2 (ja) | 2024-01-11 |
| JP2024023208A (ja) | 2024-02-21 |
| MX2020010853A (es) | 2020-11-06 |
| SI3781172T1 (sl) | 2023-11-30 |
| US12059496B2 (en) | 2024-08-13 |
| FI3781172T3 (fi) | 2023-10-02 |
| US20250170061A1 (en) | 2025-05-29 |
| EP3781172A1 (en) | 2021-02-24 |
| EP3781172B1 (en) | 2023-08-30 |
| KR20210003117A (ko) | 2021-01-11 |
| US20210030677A1 (en) | 2021-02-04 |
| CA3096968A1 (en) | 2019-10-24 |
| JP2021521191A (ja) | 2021-08-26 |
| RS64891B1 (sr) | 2023-12-29 |
| PL3781172T3 (pl) | 2024-02-12 |
| ES2959435T3 (es) | 2024-02-26 |
| SMT202300391T1 (it) | 2024-01-10 |
| AU2019254515B9 (en) | 2025-06-26 |
| EP4338743A1 (en) | 2024-03-20 |
| AU2025201451A1 (en) | 2025-03-20 |
| HUE064198T2 (hu) | 2024-03-28 |
| PT3781172T (pt) | 2023-10-11 |
| DK3781172T3 (da) | 2023-10-02 |
| CN112004540A (zh) | 2020-11-27 |
| LT3781172T (lt) | 2023-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eljaaly et al. | Plazomicin: a novel aminoglycoside for the treatment of resistant Gram-negative bacterial infections | |
| Falagas et al. | Fosfomycin: use beyond urinary tract and gastrointestinal infections | |
| Nwabuife et al. | Liposomal delivery systems and their applications against Staphylococcus aureus and methicillin-resistant Staphylococcus aureus | |
| CN109549925B (zh) | 用于治疗细菌感染的定制脂质体 | |
| SI1991201T1 (en) | NEBULISED ANTIBIOTICS FOR INHALATION THERAPY | |
| HRP20231405T1 (hr) | Liječenje upale pluća | |
| MX2007007235A (es) | Combinacion de antibioticos para proporcionar una solucion total al tratamiento de infecciones. | |
| Segarra-Newnham et al. | Pharmacotherapy for methicillin-resistant Staphylococcus aureus nosocomial pneumonia | |
| JP2015514093A5 (hr) | ||
| EP3781210B1 (en) | Treatment of hypotension with sepsis or septic shock | |
| CA2737879C (en) | Single unit carbapenem aminoglycoside formulations | |
| Bassetti et al. | Ten old antibiotics that will never disappear | |
| Maddix et al. | Do we need an intravenous fluoroquinolone? | |
| GOODHART | Treatment of uncomplicated genital gonorrhea | |
| YANG et al. | The drug resistant mechanisms and the solving strategies of Carbapenem-resistant Klebsiella pneumonia | |
| Brown | Once daily ceftriaxone in the treatment of lower respiratory tract infections | |
| WO2010062933A1 (en) | Methods for wound treatment and healing using limonene-based compositions | |
| Karp et al. | Management of infections in neutropenic patients: new opportunities and emerging challenges | |
| Anzueto et al. | Safety and efficacy of clarithromycin vs cefuroxime axetil in the treatment of acute bacterial exacerbation of chronic bronchitis. | |
| Beev | Spectinomycin-present, future and alternatives | |
| Simmer et al. | Erythromycin (2× 1 g) as a regimen for community-acquired pneumonia | |
| Grassi | Comparative clinical efficacy of cefetamet pivoxil in lower respiratory tract infection | |
| WACHTER | Iclaprim Comparable to Linezolid for Skin Infection | |
| Matthew et al. | Study of antimicrobial activity of gel for treatment of dental disease | |
| Alvarez Lerma et al. | Clinical experience with levofloxacin in the treatment of pneumonia in ICU patients |